PubMed:11535117
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/11535117","sourcedb":"PubMed","sourceid":"11535117","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/11535117","text":"Human glycosaminoglycan glucuronyltransferase I gene and a related processed pseudogene: genomic structure, chromosomal mapping and characterization.\nHere we describe the characterization of the human glycosaminoglycan glucuronyltransferase I gene (GlcAT-I) and a related pseudogene. The GlcAT-I gene was localized to human chromosome 11q12-q13 by in situ hybridization of metaphase chromosomes. GlcAT-I spanned 7 kb of human genomic DNA and was divided into five exons. Northern blot analysis showed that GlcAT-I exhibited ubiquitous but markedly different expressions in the human tissues examined. The GlcAT-I promoter was approx. 3-fold more active in a melanoma cell line than in a hepatoma cell line, providing evidence for the differential regulation of the gene's expression. Stepwise 5' deletions of the promoter identified a strong enhancer element between -303 and -153 bp that included binding motifs for Ets, CREB (cAMP-response-element-binding protein) and STAT (signal transducers and activators of transcription). Screening of a human genomic library identified one additional distinct genomic clone containing an approx. 1.4 kb sequence region that shared an overall 95.3% nucleotide identity with exons 1-5 of GlcAT-I. However, a lack of intron sequences, as well as the presence of several nucleotide mutations, insertions and deletions that disrupted the potential GlcAT-I reading frame, suggested that the clone contained a processed pseudogene. The pseudogene was localized to chromosome 3. The human genome therefore contains two related GlcAT-I genes that are located on separate chromosomes.","tracks":[{"project":"PMID_GLOBAL","denotations":[{"id":"T1","span":{"begin":658,"end":666},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":687,"end":695},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005105"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0007256"},{"subj":"T1","pred":"source","obj":"PMID_GLOBAL"},{"subj":"T2","pred":"source","obj":"PMID_GLOBAL"}]},{"project":"glycogenes","denotations":[{"id":"PD-GlycoGenes20190927-B_T1","span":{"begin":249,"end":256},"obj":"https://acgg.asia/db/ggdb/info/gg155"},{"id":"PD-GlycoGenes20190927-B_T2","span":{"begin":288,"end":295},"obj":"https://acgg.asia/db/ggdb/info/gg155"},{"id":"PD-GlycoGenes20190927-B_T3","span":{"begin":396,"end":403},"obj":"https://acgg.asia/db/ggdb/info/gg155"},{"id":"PD-GlycoGenes20190927-B_T4","span":{"begin":506,"end":513},"obj":"https://acgg.asia/db/ggdb/info/gg155"},{"id":"PD-GlycoGenes20190927-B_T5","span":{"begin":605,"end":612},"obj":"https://acgg.asia/db/ggdb/info/gg155"},{"id":"PD-GlycoGenes20190927-B_T6","span":{"begin":1228,"end":1235},"obj":"https://acgg.asia/db/ggdb/info/gg155"},{"id":"PD-GlycoGenes20190927-B_T7","span":{"begin":1385,"end":1392},"obj":"https://acgg.asia/db/ggdb/info/gg155"},{"id":"PD-GlycoGenes20190927-B_T8","span":{"begin":1561,"end":1568},"obj":"https://acgg.asia/db/ggdb/info/gg155"}],"attributes":[{"subj":"PD-GlycoGenes20190927-B_T1","pred":"source","obj":"glycogenes"},{"subj":"PD-GlycoGenes20190927-B_T2","pred":"source","obj":"glycogenes"},{"subj":"PD-GlycoGenes20190927-B_T3","pred":"source","obj":"glycogenes"},{"subj":"PD-GlycoGenes20190927-B_T4","pred":"source","obj":"glycogenes"},{"subj":"PD-GlycoGenes20190927-B_T5","pred":"source","obj":"glycogenes"},{"subj":"PD-GlycoGenes20190927-B_T6","pred":"source","obj":"glycogenes"},{"subj":"PD-GlycoGenes20190927-B_T7","pred":"source","obj":"glycogenes"},{"subj":"PD-GlycoGenes20190927-B_T8","pred":"source","obj":"glycogenes"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"PMID_GLOBAL","color":"#93eca2","default":true},{"id":"glycogenes","color":"#ec939d"}]}]}}